An NRP1/MDM2‐Targeted D‐Peptide Supramolecular Nanomedicine for High‐Efficacy and Low‐Toxic Liver Cancer Therapy. Issue 9 (9th March 2021)

• Record Type: Journal Article
• Authors: Zhou, Yunjiang; Chen, Yaxin; Tan, Yingying; Hu, Rong; Niu, Miao‐Miao
• Is Part Of: Advanced healthcare materials. Volume 10:Issue 9(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-03-09
• Subjects: D‐peptides -- liver cancer therapy -- MDM2 -- NRP1 -- supramolecular nanomedicine; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/adhm.202002197
• Languages: English
• ISSNs: 2192-2640

Abstract

Abstract: Supramolecular nanomedicines based on self‐assembly of D‐peptides have been of great interest as potential candidates for cancer therapy. Neuropilin‐1 (NRP1) and mouse double minute 2 (MDM2) have been considered as the anticancer targets because of their overexpression in cancers. However, NRP1/MDM2‐targeted D‐peptide supramolecular nanomedicines remain unreported. Here, a potent anticancer D‐peptide supramolecular nanomedicine targeting NRP1 and MDM2, termed as NMTP‐5, is identified by using structure‐based virtual screening techniques. NMTP‐5 exhibits good biostability and strong cellular uptake performance. Moreover, NMTP‐5 displays strong anticancer activity to SK‐Hep‐1 cells in vitro and in vivo, with no apparent host toxicity. This work demonstrates that NMTP‐5 can be used as a potential chemotherapeutic agent for the treatment of liver cancer. Abstract : Here, a potent anticancer supramolecular nanomedicine targeting neuropilin‐1 (NRP1) and mouse double minute 2 (MDM2), termed as NMTP‐5, is reported. After entering the cytosol of cancer cell by targeting NRP1, NMTP‐5 up‐regulates the level of p53 by interfering MDM2‐p53 interaction and induces cell death. Therefore, NMTP‐5 can be used as a potential chemotherapeutic agent for liver cancer therapy.